Key Points
Intuitive Surgical's sales and adjusted earnings per share rose by 23% and 38%.
Total procedures grew by 17%, while instrument and accessory sales jumped by 23%.
Best yet, the company continues to expand internationally and innovate solutions that help maintain its leadership position.
- 10 stocks we like better than Intuitive Surgical ›
Shares of leading robotic-assisted surgery (RAS) specialist Intuitive Surgical (NASDAQ: ISRG) are up 8% as of noon ET on Wednesday after the company sailed past Wall Street's expectations with its first-quarter earnings. Intuitive Surgical grew sales and adjusted earnings per share by 23% and 38%, respectively, and guided that its next-gen da Vinci system will see procedure growth of 13.5% to 15.5% this year, spurring the stock's healthy rally today.
Intuitive Surgical reported that:
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
- total procedures grew 17%
- Ion procedures (bronchoscopies for early lung cancer detection) increased 39%
- overall instrument placements grew roughly 4%
- instrument and accessory sales grew 23%
- recurring revenue (accessories and services) now equals 86% of total revenue
- it repurchased 0.65% of its shares outstanding in Q1 for $1.1 billion
Image source: Getty Images.
In simplest terms, it was an excellent quarter for Intuitive Surgical, as the company delivered its 13th-straight quarter of double-digit sales growth or higher. On top of the figures listed above, Intuitive Surgical delivered 19% growth in da Vinci procedures outside of the United States. These international markets now account for 38% of total da Vinci volume and highlight steady adoption internationally as "expanded reimbursement coverage and policy changes in Japan and Europe" help fuel global expansion.
Elsewhere, Intuitive Surgical continues to make incremental innovations that help keep the company the leader in its niche. One example of this is its force-feedback instrumentation, which reduces tissue forces and improves surgical outcomes. President David Rosa spoke about the potential of this new instrumentation, saying, "In March, we received FDA 510(k) clearance for additional uses of our Force Feedback instruments. Five of 6 instruments are now cleared for 15 uses, while our Mega SutureCut Needle Driver is cleared for 10 uses."
Powered by innovations like these -- paired with the long-term ambition to make telesurgery (remote RAS) common -- Intuitive Surgical's growth story is far from over in my eyes. Trading at 49 times forward earnings, Intuitive Surgical commands a well-deserved premium valuation, but considering its track record of double-digit sales growth and industry-leading innovation, I'm happy to keep adding to my shares over time.
Should you buy stock in Intuitive Surgical right now?
Before you buy stock in Intuitive Surgical, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intuitive Surgical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $499,277!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,225,371!*
Now, it’s worth noting Stock Advisor’s total average return is 972% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 22, 2026.
Josh Kohn-Lindquist has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
